Flucytosine microbiology

# Microbiology

## Mechanism of Action
Flucytosine is taken up by fungal organisms via the enzyme cytosine permease. Inside the fungal cell, flucytosine is rapidly converted to fluorouracil by the enzyme cytosine deaminase. Fluorouracil exerts its antifungal activity through the subsequent conversion into several active metabolites, which inhibit protein synthesis by being falsely incorporated into fungal RNA or interfere with the biosynthesis of fungal DNA through the inhibition of the enzyme thymidylate synthetase.

## Activity In Vitro
Flucytosine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections, however 
the in vitro activity of flucytosine is affected by the test conditions. It is essential to follow the approved standard method guidelines.
- Candida albicans, Cryptococcus neoformans:
The following in vitro data are available, but their clinical significance is unknown.
Flucytosine exhibits in vitro minimum inhibitory concentrations (MIC values) of 4 g/mL, or less against most (90%) strains of the following microorganisms, however, the safety and effectiveness of flucytosine in treating clinical infections due to these microorganisms have not been established in adequate and well control trials.
- Candida dubliniensis, Candida glabrata, Candida guilliermondii, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Candida krusei should be considered to be resistant to flucytosine.
- Cryptococcus neoformans:
No interpretive criteria have been established for Cryptococcus neoformans.
- Candida species:
Broth Dilution Techniques are Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of Candida spp. to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth)1 with standardized inoculum concentrations and standardized concentrations of flucytosine powder. The MIC values should be interpreted according to the criteria in Table 1.
A report of Susceptible indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected. Because of other significant host factors, in vitro susceptibility may not correlate with clinical outcomes.
Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard flucytosine powder should provide the range of MIC values noted in Table 2. NOTE: Quality control microorganisms are specific strains of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within fungi; the specific strains used for microbiological control are not clinically significant.

## Drug Resistance
Flucytosine resistance may arise from a mutation of an enzyme necessary for the cellular uptake or metabolism of flucytosine or from an increased synthesis of pyrimidines, which compete with the active metabolites of flucytosine (fluorinated antimetabolites). Resistance to flucytosine has been shown to develop during monotherapy after prolonged exposure to the drug.
Candida krusei should be considered to be resistant to flucytosine.

## Drug Combination
Antifungal synergism between flucytosine and polyene antibiotics, particularly amphotericin B has been reported in vitro. Ancobon is usually administered in combination with amphotericin B due to lack of cross-resistance and reported synergistic activity of both drugs.